Exact Sciences 3 Essential Cancer Tests Explained 

By Davis Wade - Writer
9 Min Read

Exact Sciences is a molecular diagnostics company that makes cancer screening and treatment-guidance tests, including Cologuard for colorectal screening and Oncotype DX for tumour profiling. Abbott completed its acquisition of the company in March 2026. Most Canadians know the name from headlines about that deal rather than from a doctor’s office, so let’s sort out what the company actually does. Ready?

What Is Exact Sciences and Where Did It Start?

The company began in 1995 in Marlborough, Massachusetts, founded by Stanley Lapidus and Anthony Shuber. Its early work centred on spotting DNA changes in stool samples. Sounds odd, right? It turned out to be a practical route to catching colorectal cancer early.

The Oncotype DX line has its own history. It carries a Genomic Health trademark, and company documents describe Genomic Health as a wholly owned subsidiary. The breast cancer version dates back to 2004, which makes it older than most people expect.

Later the headquarters moved to Madison, Wisconsin, where the business grew into a major employer. When the Abbott deal was announced it had roughly 7,000 team members and was projected to pass 3 billion US dollars in revenue for the year.

What Tests Does Exact Sciences Make?

Three product families carry most of the weight. Two are well established. One group is newer, and we should treat it a little differently.

Cologuard and Cologuard Plus

Cologuard has been available since 2014, and company fact sheets once cited more than 8 million people screened. It is an at-home stool DNA test for average-risk adults aged 45 and older. You collect a sample, send it to a lab and wait for results. No bowel prep. No time off work. The company reports that the original version detects 92 per cent of colon cancers.

Cologuard Plus came later. The company reports detection of 95 per cent of colorectal cancers and about 40 per cent fewer unnecessary follow-ups. Those are company figures, so think of them as claims to discuss with a clinician rather than promises.

One limit matters a lot. Cologuard is not meant for high-risk people, such as someone with a strong family history or earlier polyps. A negative result also does not mean you never need testing again. Your doctor sets the schedule.

Oncotype DX

This family of tests reads gene activity inside a tumour. The breast version looks at 21 genes to estimate recurrence risk, and the company says it also helps predict whether chemotherapy is likely to help. It says the test appears in major breast cancer guidelines and is offered in more than 90 countries. Versions exist for colon and prostate cancers too.

Oncodetect and Cancerguard

Oncodetect looks for molecular residual disease, meaning tiny traces of cancer left behind after treatment. Cancerguard is a multi-cancer early detection test. Both are newer, and Oncodetect launched as a US-only offering. Newer tests usually carry less long-term evidence than screening tools with decades of use, so a bit of healthy scepticism fits here. A test that flags a possible cancer signal is also not a diagnosis. It starts a conversation with your doctor, nothing more.

Why Did Abbott Buy Exact Sciences?

Abbott announced the deal in November 2025 at 105 US dollars per share, putting the equity value near 21 billion US dollars. It closed on March 23, 2026, and the company became a wholly owned subsidiary.

Why would a health-care giant spend that much? My read is reach. Abbott serves people in more than 160 countries, and its diagnostics business gained a cancer franchise it did not have before. Abbott also said it expected about 3 billion US dollars in added sales for 2026.

There was a people side to the story as well. Kevin Conroy, the chairman and chief executive, was expected to stay on in an advisory role to support the transition.

Will that reach make access easier for Canadian patients? Nobody can answer that yet.

Can You Get Exact Sciences Tests in Canada?

Short answer: it depends on the test and the province.

While reading the company’s own public materials, I noticed one line repeated again and again. Availability outside the United States differs by country. Cologuard is described as a United States test, while Oncotype DX has far wider international reach. So please don’t assume.

Canadian provinces run their own colorectal screening programs, and most rely on the fecal immunochemical test, known as FIT, for average-risk adults. It checks stool for hidden blood. That makes it a different tool from a stool DNA test. If you are 50 or older, ask your family doctor or your provincial program what is offered where you live, and ask about cost too. 

Not sure what to say at the appointment? Three questions cover most of it. Which screening test does my province offer? How often should I repeat it? What happens next if the result is positive? I think a short list like that makes the visit far less stressful.

For tumour profiling after a breast cancer diagnosis, your oncology team is the right place to start. Reading from the United States? Your doctor and your insurance plan will guide what is covered.

Does Exact Sciences Have Anything to Do With Maths and Physics?

Not directly. The same phrase also names a group of academic fields, mathematics and physics among them, where results can be measured and calculated with precision. The company shares those words, and it is a fair guess that rigour is the image it wants.

Search results mix both meanings, which is why I included this section. If you came looking for the academic meaning, a university department page will serve you better than this article.

What Should You Take Away From All This?

Here is the short version. Exact Sciences built its name on at-home colorectal screening and tumour-based gene testing, and now sits inside a company with global reach. For you, the useful step is a simple one. Talk with your doctor about which screening or testing options are actually available in your province.

This article is general information and not medical advice. Test performance figures come from the company and have not been independently confirmed here.

FAQ

Is Cologuard available in Canada?

Company materials list Cologuard as available in the United States, and I could not find confirmation of Canadian availability. Provincial programs generally use FIT instead. Ask your doctor before ordering anything from abroad.

Who owns Exact Sciences now?

Abbott. The acquisition closed on March 23, 2026, and the company now operates as a wholly owned subsidiary. The original announcement said it would keep a presence in Madison.

Is Oncotype DX covered in Canada?

Coverage can depend on the province and sometimes the hospital. I could not verify one national rule, so ask your oncology team how it works where you are treated.

What is the difference between a FIT and a stool DNA test?

A FIT looks for hidden blood in stool. A stool DNA test such as Cologuard looks for altered DNA as well as blood. Both are screening tools rather than diagnoses, and a positive result usually leads to a colonoscopy.

By Davis Wade Writer
Follow:
Davis Wade is a content researcher focused on Canadian real estate trends, working with local market data and public listing sources to help readers compare cities and neighbourhoods before they buy.
Leave a comment